نتائج البحث - "Benjamin M. Ellingson"

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 23, iss 19
Clinical Cancer Research, 23(19), 5745-5756. American Association for Cancer Research Inc.

مصطلحات موضوعية: Vascular Endothelial Growth Factor A, Male, Oncology, Cancer Research, Imaging biomarker, Pyridines, Phases of clinical research, Angiogenesis Inhibitors, chemistry.chemical_compound, 0302 clinical medicine, Lomustine, Receptors, Medicine, Anilides, Cancer, Aflibercept, Tumor, Vascular Endothelial Growth Factor, Middle Aged, Bevacizumab, Local, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Biomedical Imaging, Female, medicine.drug, medicine.medical_specialty, Cabozantinib, Recombinant Fusion Proteins, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Article, Disease-Free Survival, Cediranib, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, Biomarkers, Tumor, Humans, Effective diffusion coefficient, Oncology & Carcinogenesis, business.industry, Neurosciences, Evaluation of treatments and therapeutic interventions, Brain Disorders, Brain Cancer, Receptors, Vascular Endothelial Growth Factor, Neoplasm Recurrence, Diffusion Magnetic Resonance Imaging, chemistry, Quinazolines, Neoplasm Recurrence, Local, Glioblastoma, business, Nuclear medicine, Biomarkers, 030217 neurology & neurosurgery

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8bba073dc3ce7c7331b542d1e654786Test
https://doi.org/10.1158/1078-0432.ccr-16-2844Test

5

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

المصدر: Nature medicine, vol 25, iss 3
Transl Cancer Res

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, medicine.medical_treatment, T-Lymphocytes, Programmed Cell Death 1 Receptor, Pembrolizumab, Medical and Health Sciences, Neurosurgical Procedures, 0302 clinical medicine, Antineoplastic Agents, Immunological, Cancer immunotherapy, Monoclonal, Tumor Microenvironment, Medicine, Humanized, Neoadjuvant therapy, Adjuvant, Cancer, Brain Neoplasms, General Medicine, Middle Aged, Neoadjuvant Therapy, Survival Rate, Immunological, Local, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Female, Patient Safety, Adult, medicine.medical_specialty, Clinical Trials and Supportive Activities, Immunology, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, Article, Antibodies, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, Adjuvant therapy, Humans, Chemotherapy, Survival rate, Aged, Tumor microenvironment, business.industry, Neurosciences, Evaluation of treatments and therapeutic interventions, Immunotherapy, Brain Disorders, Brain Cancer, 030104 developmental biology, Neoplasm Recurrence, Immunization, Neoplasm Recurrence, Local, business, Glioblastoma

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e3ae39dddd1a3863fed4db0b0d75312Test
https://escholarship.org/uc/item/7gf847t7Test

6

Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden

المؤلفون: Laura Dovek, Timothy F. Cloughesy, Myung-Shin Sim, Albert Lai, Arliene Ravelo, Huy Tram N. Nguyen, Liang Yen Liu, Robert Harris, Byram Ozer, Daniel Lenchner, Richard M. Green, Nhung T Nguyen, Robert Elashoff, Benjamin M. Ellingson, Nicolas Sommer, Phioanh L. Nghiemphu

المصدر: Neuro-oncology practice, vol 6, iss 2

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5eb25c25c268ce6c066359814f88fcdTest
https://escholarship.org/uc/item/03j1n5pdTest

7

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

المؤلفون: Ryo Nishikawa, Lauren E. Abrey, Robert J. Harris, Benjamin M. Ellingson, Roger Henriksson, Ararat Chakhoyan, Wolfgang Wick, Catalina Raymond, Olivier Chinot, Kevin Leu, Timothy F. Cloughesy, Josep Garcia, Arnav Mehta, Warren Mason, Davis C. Woodworth, Frank Saran, Whitney B. Pope

المساهمون: Institut de neurophysiopathologie (INP), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Service d’Oncologie Médicale [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)

المصدر: Ellingson, BM; Abrey, LE; Garcia, J; Chinot, O; Wick, W; Saran, F; et al.(2018). Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. NEURO-ONCOLOGY, 20(11), 1525-1535. doi: 10.1093/neuonc/noy064. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1c51c6bdTest
Neuro-Oncology
Neuro-Oncology, Oxford University Press (OUP), 2018, ⟨10.1093/neuonc/noy064⟩
Neuro-Oncology, 2018, ⟨10.1093/neuonc/noy064⟩
Neuro-oncology, vol 20, iss 11

مصطلحات موضوعية: Male, Oncology, Cancer Research, [SDV]Life Sciences [q-bio], law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, 80 and over, ComputingMilieux_MISCELLANEOUS, Cancer, Aged, 80 and over, response assessment, medicine.diagnostic_test, Brain Neoplasms, Chemoradiotherapy, Middle Aged, Prognosis, Magnetic Resonance Imaging, Tumor Burden, Bevacizumab, Survival Rate, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Female, 4.2 Evaluation of markers and technologies, medicine.drug, MRI, Adult, medicine.medical_specialty, Adolescent, Oncology and Carcinogenesis, Clinical Investigations, Newly diagnosed, bevacizumab, Placebo, GBM, Young Adult, 03 medical and health sciences, Rare Diseases, Double-Blind Method, Clinical Research, Internal medicine, Temozolomide, medicine, Humans, Oncology & Carcinogenesis, Survival rate, Aged, clinical trials, business.industry, T1 subtraction, Neurosciences, glioblastoma, Magnetic resonance imaging, Brain Disorders, Brain Cancer, Clinical trial, Neurology (clinical), Glioblastoma, business, 030217 neurology & neurosurgery, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b6bd15c9d5ce9e742e59326a3e480bfTest
http://www.escholarship.org/uc/item/1c51c6bdTest

8

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

المساهمون: Département de neurooncologie, Hôpital de la Timone [CHU - APHM] (TIMONE), Department of Radiation Sciences, Oncology, Umeå University, Department of Neurooncology, Heidelberg University Hospital [Heidelberg], Hadassah Hebrew University Medical Center [Jerusalem], Massachusetts General Hospital [Boston], Loughborough University, School of Environment and Technology, University of Sussex, Department of Molecular Medicine, Mayo Clinic, Hôpital de la Timone [CHU - APHM] ( TIMONE ), Massachusetts General Hospital [Boston] ( MGH )

المصدر: Neuro-Oncology
Neuro-Oncology, Oxford University Press (OUP), 2018, ⟨10.1093/neuonc/noy053⟩
Neuro-Oncology, Oxford University Press (OUP), 2018, 〈10.1093/neuonc/noy053〉
Neuro-oncology, vol 20, iss 9
Ellingson, BM; Abrey, LE; Nelson, SJ; Kaufmann, TJ; Garcia, J; Chinot, O; et al.(2018). Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. NEURO-ONCOLOGY, 20(9), 1240-1250. doi: 10.1093/neuonc/noy053. UCLA: Retrieved from: http://www.escholarship.org/uc/item/0v78z01zTest

مصطلحات موضوعية: Oncology, Male, Cancer Research, contrast-enhancing tumor volume, [SDV]Life Sciences [q-bio], Contrast Media, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, ComputingMilieux_MISCELLANEOUS, Cancer, Vorinostat, Chemoradiotherapy, Middle Aged, Prognosis, Magnetic Resonance Imaging, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, Residual, 6.1 Pharmaceuticals, Female, medicine.drug, medicine.medical_specialty, Prognostic factor, Bevacizumab, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Newly diagnosed, bevacizumab, Imaging data, GBM, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Overall survival, Temozolomide, Humans, Oncology & Carcinogenesis, Retrospective Studies, Postoperative Care, clinical trials, [ SDV ] Life Sciences [q-bio], business.industry, T1 subtraction, Neurosciences, O-6-methylguanine-DNA methyltransferase, Evaluation of treatments and therapeutic interventions, medicine.disease, Image Enhancement, new glioblastoma, nervous system diseases, Brain Disorders, Clinical trial, Brain Cancer, Neoplasm, Neurology (clinical), business, Glioblastoma, 030217 neurology & neurosurgery, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5bde2fd7ff93ddc9c95a933bfa0dc0aTest
https://hal-amu.archives-ouvertes.fr/hal-01814367Test

تنقيح النتائج